Needham softens view on Amphastar in premarket analyst action

|About: Amphastar Pharmaceutic... (AMPH)|By:, SA News Editor

NovaBay Pharmaceuticals (NYSEMKT:NBY) downgraded to Neutral with a $1.25 (17% downside risk) price target at H.C. Wainwright after salesforce reduction and interim CEO departure.

Amphastar Pharmaceuticals (NASDAQ:AMPH) downgraded to Hold at Needham. Shares down 5% premarket.

Subscribe for full text news in your inbox